Burns – Pipeline Review, H2 2012
SUMMARY
Global Markets Direct’s, 'Burns - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
SUMMARY
Global Markets Direct’s, 'Burns - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE
- A snapshot of the global therapeutic scenario for Burns.
- A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Burns pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Burns.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Burns Overview
Therapeutics Development
An Overview of Pipeline Products for Burns
Burns Therapeutics under Development by Companies
Burns Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Burns Therapeutics – Products under Development by Companies
Burns Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Burns Therapeutics Development
MediWound Ltd.
CytoTools AG
Shenzhen Beike Biotechnology Co., Ltd.
Healthpoint, Ltd.
TetraLogic Pharmaceuticals
Glycotex, Inc.
NanoBio Corporation
Adocia
Fibrocell Sciences, Inc.
Se-cure Pharmaceuticals Ltd.
AlgiPharma AS
Birken GmbH
Burns – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Mebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-SKN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Necrostatin Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azficel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
opebacan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amnion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caspofungin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debrase Gel Dressing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
becaplermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cultured Autologous Keratinocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levamizole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleogel-S-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propranolol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N2 Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burns Therapeutics – Drug Profile Updates
Burns Therapeutics – Discontinued Products
Burns Therapeutics - Dormant Products
Burns – Product Development Milestones
Featured News & Press Releases
Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment
Oct 12, 2010: Nanobio And The University Of Michigan Awarded $1.5M Department Of Defense Grant To Study Topical Anti-Infective Treatment For Combat Related Injuries
Sep 14, 2009: NanoBio Presents Key Data On The Use Of Nanoemulsions To Treat Burn Wound Infections
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting
Jan 16, 2008: Glycotex, Inc. Receives $0.5 Million From Second Tranche Of Private Share Placement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Burns, H2 2012
Products under Development for Burns – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
MediWound Ltd., H2 2012
CytoTools AG, H2 2012
Shenzhen Beike Biotechnology Co., Ltd., H2 2012
Healthpoint, Ltd., H2 2012
TetraLogic Pharmaceuticals, H2 2012
Glycotex, Inc., H2 2012
NanoBio Corporation, H2 2012
Adocia, H2 2012
Fibrocell Sciences, Inc., H2 2012
Se-cure Pharmaceuticals Ltd., H2 2012
AlgiPharma AS, H2 2012
Birken GmbH, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Burns Therapeutics – Drug Profile Updates
Burns Therapeutics – Discontinued Products
Burns Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Burns, H2 2012
Products under Development for Burns – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Burns Overview
Therapeutics Development
An Overview of Pipeline Products for Burns
Burns Therapeutics under Development by Companies
Burns Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Burns Therapeutics – Products under Development by Companies
Burns Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Burns Therapeutics Development
MediWound Ltd.
CytoTools AG
Shenzhen Beike Biotechnology Co., Ltd.
Healthpoint, Ltd.
TetraLogic Pharmaceuticals
Glycotex, Inc.
NanoBio Corporation
Adocia
Fibrocell Sciences, Inc.
Se-cure Pharmaceuticals Ltd.
AlgiPharma AS
Birken GmbH
Burns – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Mebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICX-SKN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Necrostatin Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azficel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
opebacan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amnion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
caspofungin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debrase Gel Dressing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
becaplermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cultured Autologous Keratinocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levamizole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleogel-S-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
propranolol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N2 Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burns Therapeutics – Drug Profile Updates
Burns Therapeutics – Discontinued Products
Burns Therapeutics - Dormant Products
Burns – Product Development Milestones
Featured News & Press Releases
Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment
Oct 12, 2010: Nanobio And The University Of Michigan Awarded $1.5M Department Of Defense Grant To Study Topical Anti-Infective Treatment For Combat Related Injuries
Sep 14, 2009: NanoBio Presents Key Data On The Use Of Nanoemulsions To Treat Burn Wound Infections
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting
Jan 16, 2008: Glycotex, Inc. Receives $0.5 Million From Second Tranche Of Private Share Placement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Burns, H2 2012
Products under Development for Burns – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
MediWound Ltd., H2 2012
CytoTools AG, H2 2012
Shenzhen Beike Biotechnology Co., Ltd., H2 2012
Healthpoint, Ltd., H2 2012
TetraLogic Pharmaceuticals, H2 2012
Glycotex, Inc., H2 2012
NanoBio Corporation, H2 2012
Adocia, H2 2012
Fibrocell Sciences, Inc., H2 2012
Se-cure Pharmaceuticals Ltd., H2 2012
AlgiPharma AS, H2 2012
Birken GmbH, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Burns Therapeutics – Drug Profile Updates
Burns Therapeutics – Discontinued Products
Burns Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Burns, H2 2012
Products under Development for Burns – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012